BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 30919233)

  • 1. Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial.
    Al-Sulaiti FK; Nader AM; Saad MO; Shaukat A; Parakadavathu R; Elzubair A; Al-Badriyeh D; Elewa H; Awaisu A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):639-652. PubMed ID: 30919233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
    Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
    J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics.
    Jorgensen SCJ; Dersch-Mills D; Timberlake K; Stewart JJ; Gin A; Dresser LD; Dalton BR
    J Antimicrob Chemother; 2021 Aug; 76(9):2237-2251. PubMed ID: 33675656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.
    Brown DL; Lalla CD; Masselink AJ
    Ther Drug Monit; 2013 Aug; 35(4):443-9. PubMed ID: 23851909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical validation of the two-point method for predicting vancomycin AUC based on peak and trough plasma concentrations.
    Wang L; Lin X; Wang L; Ye H; Lin Y; Ruan J; Shi S
    Int J Clin Pharm; 2022 Dec; 44(6):1325-1331. PubMed ID: 36136207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of the vancomycin 24-h area under the concentration-time curve (AUC
    Issaranggoon Na Ayuthaya S; Katip W; Oberdorfer P; Lucksiri A
    Int J Infect Dis; 2020 Mar; 92():151-159. PubMed ID: 31935538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant
    Marko R; Hajjar J; Nzeribe V; Pittman M; Deslandes V; Sant N; Cowan J; Kyermentang K; Ramsay T; Zelenitsky S; Kanji S
    Can J Hosp Pharm; 2021; 74(4):334-343. PubMed ID: 34602621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.
    Haeseker M; Croes S; Neef C; Bruggeman C; Stolk L; Verbon A
    Ther Drug Monit; 2016 Feb; 38(1):120-6. PubMed ID: 26418699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Britt NS; Patel N; Horvat RT; Steed ME
    Antimicrob Agents Chemother; 2016 May; 60(5):3070-5. PubMed ID: 26953202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
    Waineo MF; Kuhn TC; Brown DL
    J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized dosing of vancomycin in geriatric patients.
    Suchánková H; Lečbychová K; Strojil J; Fürst T
    Epidemiol Mikrobiol Imunol; 2020; 69(4):172-180. PubMed ID: 33445941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic analysis of vancomycin in patients with
    Tochikura N; Matsumoto C; Iwabuchi S; Aso H; Fukushima S; Ootsuka S; Ooba N; Ishihara M; Nakajima H; Umemura H; Nakayama T
    Eur J Hosp Pharm; 2023 Mar; ():. PubMed ID: 36868850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.
    Prybylski JP
    Clin Pharmacokinet; 2017 Mar; 56(3):263-272. PubMed ID: 27389404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections.
    Clark L; Skrupky LP; Servais R; Brummitt CF; Dilworth TJ
    Ther Drug Monit; 2019 Aug; 41(4):483-488. PubMed ID: 30817704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
    Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dosing and monitoring of vancomycin: what is the best way forward?
    Drennan PG; Begg EJ; Gardiner SJ; Kirkpatrick CMJ; Chambers ST
    Int J Antimicrob Agents; 2019 Apr; 53(4):401-407. PubMed ID: 30599240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.